Lupin has announced the launch of a strategic partnership program aimed at expanding the reach of its PrecisionSphere™ long-acting injectable (LAI) platform, developed by Nanomi B.V. The program seeks collaborations with companies aiming to extend their product lifecycles, leveraging Lupin’s regulatory expertise and manufacturing capabilities. This initiative promises improved injectability and consistent drug concentrations, offering optimized therapeutic delivery for various patient needs and potentially extending the patent life of partner products.
Strategic Collaboration for LAI Platform
Lupin Limited has introduced a strategic partnership program focused on its PrecisionSphere™ technology. This program is designed to broaden the application of their long-acting injectable (LAI) platform. The official announcement was made on October 09, 2025, highlighting the company’s commitment to innovation in drug delivery systems.
PrecisionSphere™ Platform Advantages
The PrecisionSphere™ platform offers several key advantages, including:
- Improved injectability through consistent particle size.
- Optimized drug levels with consistent concentrations.
- Potential for extended patent life for partner products.
Benefits for Patients and Healthcare Professionals
The strategic partnership is poised to benefit both patients and healthcare professionals through the following:
- Reduced injection frequency, enhancing patient convenience and compliance.
- Improved treatment outcomes with controlled drug delivery.
- More efficient therapeutic dose management by healthcare providers.
Statements from Lupin Leadership
Dr. Fabrice Egros, President – Corporate Development, Lupin, noted that this program leverages the proven track record of successful strategic partnerships and will expand patient access to advanced LAI treatments.
Dr. Shahin Fesharaki, Chief Scientific Officer, Lupin, emphasized that PrecisionSphere™ reflects Lupin’s commitment to innovation by lowering entry barriers for developing LAIs.
Source: BSE
